Magdalena is a writer with a passion for bridging the gap between the people performing research, and those who want or need to understand it. She writes about medical science and drug discovery. She holds an MS in Pharmaceutical Bioscience and a PhD — spanning the fields of psychiatry, immunology, and neuropharmacology — from Karolinska Institutet in Sweden.
Vagal nerve stimulation may effectively reduce seizures in children with Angelman syndrome with treatment-refractory epilepsy, a case series report shows. The device also made the children more alert and attentive, ... Read more
In rare cases, loss of part of the UBE3A gene can lead to Angelman syndrome, Spanish researchers report. The team at the Autonomous University of Barcelona based their conclusion on a case ... Read more
Ovid Therapeutics is recruiting adult patients with Angelman syndrome to a Phase 2 clinical trial of gaboxadol, a compound that aims to treat the disease by restoring lost inhibitory brain ... Read more
Machine learning methods could improve the ability of clinical trials to detect if treatments targeting the brain — such as for Angelman syndrome — are effective, as these methods are more ... Read more
The successful development of meaningful therapies for rare diseases such as Angelman syndrome requires scientists to find out what matters most to patients with these conditions, two European researchers argued ... Read more
Agilis Biotherapeutics said its Angelman syndrome gene therapy development is on track, with initial animal studies making way for tests needed before the therapy can be tried in humans. The ... Read more
A global online Angelman syndrome registry that Australian researchers started in September 2016 has researched a critical mass, its founders report. Two hundred eighty-six people joined the registry in its ... Read more